James C. Shehan is quoted in The Center for Biosimilars in an article discussing the nomination of Stephen Hahn to be the next FDA commissioner and whether his selection would mean continued advancement for biosimilars, as was the case during Scott Gottlieb and Ned Sharpless’s tenures. Shehan notes a major shift in the U.S. market’s need for biosimilars, with Gottlieb’s time as commissioner representing a “quantum leap in terms of activism.”
Relevant Insights
-
PROFESSIONALS | Lawyers
Access the profiles of the more than 350 Lowenstein Sandler lawyers who provide critical legal counsel to clients in virtually every sector of the global economy...
-
NEWS & INSIGHTS | Firm News
Discover the latest updates and developments about Lowenstein Sandler...
-
NEWS & INSIGHTS | Publications
Access our insightful thought leadership, including articles, client alerts, and blog posts...